Spero pads syndicate, lands $51.7M series C for pipeline of antibacterials
Spero Therapeutics LLC completed a $51.7 million series C preferred financing led by new investor GV (formerly Google Ventures) with the participation of additional new investors RA Capital Management and Rock Springs Capital as well as existing investors, including Atlas Venture, S.R. One Ltd., MRL Ventures Fund, Lundbeckfonden Ventures, the Kraft Group and Osage University Partners.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST